Introduction
Infantile spasms, as part or not of West syndrome, 1 have been the subject of numerous reviews throughout the years. 2 While pathophysiological mechanisms remain poorly understood [2] [3] [4] [5] and the drug treatment options limited to a few anticonvulsants, much light has been thrown onto causes or associations mainly due to the progress in diagnostic means and to a lesser degree, to epidemiological data. 6 Because of the relatively rare incidence of this condition of 1 per 2000-6000 live births, 7, 8 the diverse classifications 9 and the multiple treatment strategies used over the years as well as the small number of prospective studies with longterm follow-up, controversy regarding the optimal treatment and long-term prognosis of the condition remains. 10 The goal of this retrospective study is to try to describe the different aetiologies of infantile spasms encountered in our clinical practice and to compare the efficacy of therapeutic modalities based on aetiology as well as to provide prognostic information on epileptic and cognitive outcome as the basis for future prospective studies looking at improving the outcome of this catastrophic form of epilepsy.
Patients and methods
We reviewed the medical records of all the children with a diagnosis of infantile spasms or West syndrome evaluated at Sainte-Justine Hospital between January 1990 and August 2003. We included all children seen either in hospital or in the outpatient clinic. The presence of hypsarrhythmia was not mandatory therefore any epileptic interictal pattern on EEG was admissible. This allowed us to measure the impact of hypsarrhythmia on outcome. However, we only included children whose EEGs were obtained at the time of clinical diagnosis and who were followed at our institution after treatment initiation. A certified electroencephalographer reviewed all the EEGs (L.C.).
Infantile spasms were classified into two groups, symptomatic and cryptogenic according to the ILAE classification of the epilepsies. 11 Patients with a definite cause/association were included in the symptomatic group. Children with cryptogenic IS were diagnosed when medical history, clinical evaluation and investigations did not lead to an aetiological diagnosis. In the absence of formal developmental evaluations, we did not classify as idiopathic IS. 19 Investigation including the Wood's lamp skin assessment, neuroimaging (MRI or CT) and basic metabolic studies (amino acids, organic acids, lactate, pyruvate and ammonia levels) were available in all patients. Further work-up (video-EEG, genetics, heart ultrasound/ MRI, cerebral PET and/or SPECT, muscle biopsy, other metabolic tests, etc. . .) was done as needed on an individual basis. Sex, age at onset of spasms, family history of epilepsy (1st and 2nd degree relatives), significant pre-/peri/post-natal insults, leadtime to clinical diagnosis (defined as the time from the initial observation of spasms to the clinical diagnosis), and the follow-up period (from clinical diagnosis to last neurology visit) were recorded. The existence of pre-, post-and concomitant seizures was also recorded. The response to the initial treatment, as well as the response time (defined as the period between treatment initiation and the cessation of spasms) was included in the database. The response to treatment was classified as follows: complete (no relapse observed after last spasm for the entire follow-up period), transient (relapse of spasms after at least a 7-day spasm free period) and no response. For purpose of analysis, we recorded both initial response to appropriate therapy and longterm clinical response. The patients who relapsed were considered as non-responders only if an increase or a change of medication was not successful in controlling their spasms. They were considered long-term responders if an increment of the initial medication or a second treatment course controlled IS on a longterm. The length of treatment was also calculated for all patients. Finally, we recorded the developmental outcome at last follow-up visit (cognitive and motor), the presence of autistic features and of attention deficit disorder with or without hyperactivity based on the neurologist's assessment.
Results

Epidemiology
A total of 80 children were included in the study, 34 females and 46 males. 15 more were excluded due to missing data. These patients were not followed at Sainte-Justine or were seen at Sainte-Justine for a second opinion usually to obtain a surgical evaluation. 50 out of the 80 remaining children had symptomatic spasms (62.5%) and 30 cryptogenic (37.5%). We encountered a vast number of aetiologies/associations in the symptomatic group. We separated them into two large categories. The first included 37 children with developmental lesions and the second 13 children acquired lesions or associations (Table 1) . Patients who relapsed on treatment or after tapering off are counted in the post-relapse control column only. In the other drug group, we included either patients who did not try vigabatrin, steroids or topiramate at any time or those who tried one of these drugs but responded only when another non-conventional treatment was added.
We had sufficient information to calculate the mean leadtime to diagnosis in 69 patients. The mean delay was 36.8 AE 69.3 days. No statistically significant difference among the symptomatic versus cryptogenic groups was observed. The mean age at diagnosis was overall 7.21 AE 4.7 months, again not different amongst the groups.
Genetics
We did not find families with multiple children affected by infantile spasms. However, a twin with cryptogenic infantile spasms shared with his identical twin a hypsarrhythmic EEG pattern. Both were treated and showed a complete response to vigabatrin. Although the sibling actually never had clinical evidence of spasms, the EEG pattern responded to therapy and his developmental outcome is normal, like his twin.
However, 15 out of 30 children (50%) with cryptogenic spasms had a positive family history of epilepsy. Among these 15 familial cases, the vast majority were males (n = 12; 80%) and 4 of them had 
Seizure types and EEG findings
18 children experienced seizures prior to developing infantile spasms. 15 out of 18 (83.3%) were diagnosed with a defined aetiology. Neonatal seizures were observed in 3 children while partial or secondarily generalized seizures were seen in 12.
32 out of 50 (64%) patients in the symptomatic group had hypsarrhythmia on their EEG at diagnosis. The most consistent association was with trisomy 21, in which 3 out of 4 children presented with hypsarrhythmia at diagnosis (75%). All had a favourable seizure outcome, a finding, which is in keeping with the literature. [12] [13] [14] In contrast, 7 children had tuberous sclerosis but only 3/7 had hypsarrhythmia, while the others showed multifocal epileptiform discharges. All children responded to treatment, but 3 had recurrent spasms, 1 with hypsarrhythmia treated with ACTH and 2 with multifocal EEG changes 1 treated with vigabatrin and the other with valproic acid and vitamin B6. 2 children with TS had persistent partial seizures post-spasms, both with initially multifocal EEGs. Post-treatment EEG remained abnormal at 1 month more often in the hypsarrhythmic group compared to the non-hypsarrhythmic group. In the symptomatic group, 6/32 children with hypsarrhythmia had a repeat EEG that became normal immediately after treatment but 3 out of these 6 eventually showed some epileptiform EEG activity. Most children showed post-spasms either a multifocal EEG pattern (n = 21) or focal discharges (n = 20). 5 children developed generalized epileptic discharges and the rest had an abnormal background without epileptic activity. 13 Finally, hypsarrhythmia persisted in 3 out of 32 symptomatic patients (9%) 1-month post-treatment none of which responded clinically. However, none went on to fulfill the diagnostic criteria for Lennox-Gastaut syndrome. 15, 16 In the cryptogenic group, 23 of 30 patients had pre-treatment hypsarrhythmia, in none did it persist after treatment. In 16, the EEG normalized at the first follow-up control with 13 going on to develop normally.
Incidence of behavioural disorders
Although most children were developmentally delayed, autistic features appeared after the onset of spasms in 1 child with tuberous sclerosis (1/7), in 2 with cortical dysplasia (2/7) and in 2 with cryptogenic spasms (1 had family history of schizophrenia). ADHD developed in 4 out of 50 symptomatic, 6 out of 30 cryptogenic spasms.
Developmental outcome
Of all symptomatic patients, only 1 child with a diagnosis of cerebral atrophy showed a normal development at the last followup visit (Table 1) . None of the children with tuberous sclerosis had a completely normal development despite 5/5 responding to vigabatrin and 1/1 to ACTH. The only child with persistent spasms only received non-conventional treatment. They all developed language delay and 5/7 also had motor delay.
Half of the children with cryptogenic infantile spasms showed no developmental delay at last follow-up (Table 1 ). All showed an early recuperation of development and arrest of spasms with treatment initiation with either ACTH (n = 11) or vigabatrin (n = 14).
Treatment outcome
Vigabatrin was given to 50 patients, 46 as first line therapy. The total recorded mean duration of treatment was 21 AE 18.9 months with a minimum of 0.2 months and a maximum of 76 months, median 14 months. ACTH and/or prednisone were given to 39 patients, 34 as first line therapy. The total recorded mean duration of treatment was 41.62 AE 60.9 days, minimum 10 and maximum 365 days (prednisone), median 28 days.
In children with cryptogenic spasms, there was no difference between vigabatrin and ACTH for seizure control (Table 1) . No statistically significant difference was found among vigabatrin's and ACTH's response times when these were given as a first choice treatment in patients who responded completely nor was there any difference in the risk of relapse.
We analyzed outcome based on aetiology for the symptomatic cases (Table 1) . Of the 23 children with developmental brain lesions treated with vigabatrin, 11 responded with complete cessation or where controlled after increasing the dosage when they relapsed. 6 children relapsed on vigabatrin, including 4 with diffuse atrophy who did not regain spasm control. For steroids, 7 of 15 responded including 1 who relapsed after an initial response. Only 1 child with focal cortical dysplasia relapsed and he was also never able to regain spasm control.
For the acquired lesions associated with IS, 4 out of 8 responded to vigabatrin with no relapse, while 4 out of 6 responded to steroids, including 1 who relapsed on treatment.
In cryptogenic IS, both drugs were highly effective with 14 out of 17 (82.3%) responding to vigabatrin and 11 of 13 to steroids (84%).
Topiramate was used in 6 patients with refractory spasms and was effective in 1 child with diffuse cerebral atrophy. A number of other anticonvulsants were tried in this population, cessation of spasms was reported in 2 children after the introduction of clonazepam (2/12) and in 1 child after valproic acid (1/18). 1 child out of 2 responded to the introduction of the ketogenic diet. Other failed treatments included vitamin B6, nitrazepam and clobazam.
Discussion
The changing epidemiology of infantile spasms
The incidence of IS is estimated to be 1 per 2000-6000 live births 7, 8 with a peak age of onset at 6 months. Each year worldwide 2 million new cases are diagnosed. 6, 17 Up to 75% of children have an underlying disorder. The principal aetiologies of spasms are hypoxic-ischemic injury, neurocutaneous syndromes, cerebral dysgenesis, inborn errors of metabolism, intrauterine or postnatal infections, and intracranial haemorrhage. 18 Due to better imaging techniques, mainly MRI, a number of patients, formerly classified as cryptogenic can now be included in the symptomatic group. In our population, we identified in 63% of patients with new-onset infantile spasms an underlying aetiology. This is slightly less than in other series probably due to the fact that only well-documented diagnoses or associations were included. For example, for hypoxic-ischemic injury to be included as a diagnosis required clinical as well as imaging evidence of injury in the first 24 h of life. 20 However, we did include in our group children with cerebral atrophy, which is a non-specific diagnosis. In our cohort, the latter was one of the most frequent aetiologies with tuberous sclerosis and focal cortical dysplasia. Indeed, malformations of brain development disorders, including atrophy and various syndromes, were the most common aetiologies with 37 out of 50 children with symptomatic cases. This is overwhelmingly more than perinatal injury (6 patients in our population) often reported as the most common cause. 21 This supports that it is therefore imperative that a complete diagnostic work-up should be performed in children with IS even those bearing a diagnosis of perinatal injury. For instance, the child in this cohort with the Aicardi syndrome was carrying a hypoxicischemic injury diagnosis to explain her early developmental delay up to the onset of spasms, when an ophthalmology evaluation was performed, and the proper diagnosis made. Significant progress has been made towards the identification of specific genes causing infantile spasms. Tuberous sclerosis was the first genetic disorder associated with IS. More recently, mutations in at least four genes predisposing to cortical dysplasias associated with IS have been identified, including: (1) LIS1, causing mainly lissencephaly, but also subcortical band heterotopia; 25 (2) DCX, causing lissencephaly in males, and subcortical band heterotopia in females; 26 (3) ARX, causing X-linked lissencephaly, corpus callosum agenesis and ambiguous genitalia; 27, 28 and (4) FLNA causing periventricular nodular heterotopia. 29 In contrast to symptomatic IS, little is known on the genetics of cryptogenic and IS. The high incidence of a positive family history in the children with cryptogenic spasms in our cohort (50%) strongly supports an underlying genetic susceptibility for this subset of IS. Finally, disruption of CDKL5 gene was found in 1 girl with cryptogenic IS. 30 Mutations in CDKL5 have been associated with atypical Rett syndrome, including IS, mental retardation, stereotypic hand movements, and episodes of hyperventilation. 31, 32 Further studies are required in our population to better understand the role of genetics in IS.
Outcome of infantile spasms
Our group and others have shown that certain aetiologies of IS appear to have a relatively better outcome. These include conditions such as tuberous sclerosis, Aicardi syndrome and trisomy 21. 22,23 In this retrospective study, we were not able to demonstrate superiority of one treatment over the other in any specific syndrome either in the short-or long-term. These results differ from the UKISS study. 35 In that prospective study, ACTH seemed to be superior to VGB in the short-term, with similar response on the long-term for both medications. ACTH was also superior to VGB in cryptogenic patients, a result we cannot confirm with our study As early control of spasms could play a role in improving cognitive outcome the authors supported ACTH as the initial treatment of IS. Obtaining prospective data using developmental scales to support this conclusion would be a major advancement in improving the treatment of IS. If we believe the cognitive impact of IS is due to the constant epileptic discharges, in our cohort the subgroup with cryptogenic spasms had a similar lead-time to diagnosis than the symptomatic group. In our population, the lead-time to clinical diagnosis was remarkably long. The mean delay to diagnosis was more than a month in both groups. And some of the children in the cryptogenic group still had a favourable outcome despite delaying treatment by more than 90 days. This suggest that some children could have a superior potential and some remain within normal limits despite the IS and hypsarrhythmia. Whether or not IS had an impact on the development of these children would require prospective developmental evaluations. The great variability in the delay to diagnosis could be explained by the atypical symptomatology of infantile spasms, which is different than those of other seizure types. But, we believe that this delay reflects the limited awareness of primary care physicians and families to IS as a consequence or complication of neurodevelopmental/early life disorders. With the benefits described in treating IS as early as possible in certain conditions like tuberous sclerosis and Aicardi syndrome, 22, 23 our data might suggest that parents and physicians treating children should be informed of IS as a possible complication (not only complex partial or generalized seizures) and even that an EEG could be part of the routine evaluation of developmentally delayed children between 3 and 10 months of age. Perhaps -in conjunction with epidemiologic studies concerning the incidence of infantile spasms in particular diseases -it might be useful to screen specific groups of children with EEG, in order to detect hypsarrhythmia (or multifocal discharges) in an early stage. 5, 6 This is re-enforced by the observation of an improved outcome in children with cryptogenic spasms treated within a month of diagnosis. 24 More than half (61%) of children in our cohort remained epileptic at the end of the spasms. Of the 31 who did not develop epilepsy following IS, 12 were symptomatic with 1 trisomy 21, 3 tuberous sclerosis, 4 cerebral atrophy, 3 post-infectious, 1 with cortical developmental disorder; 19 were cryptogenic. Another important observation is that despite a follow-up of more than 4 years, no case fulfilled the criteria for Lennox-Gastaut syndrome. Indeed, while it is said that 25% of children with IS go on to develop Lennox-Gastaut syndrome, our children with multiple seizure types, whether or not tonic seizures were observed, did not show the typical slow spike and wave pattern of Lennox-Gastaut syndrome. These children evolved more often with the multifocal epileptic pattern originally described by Markand, Blume and Ohtahara and recently revisited. 33 Whether this improves longterm outcome remains to be demonstrated.
Conclusion
Our results suggest that despite the fact that infantile spasms are a severe neurological condition, diagnosis is too often delayed. Education is therefore required for parents and health care providers involved in the care of children with developmental delay to try and limit this as early treatment might improve outcome. 24 The optimal treatment strategy remains unknown, but in our population the two major available drugs (vigabatrin and ACTH) lead to a similar response rate. 34 Finally, the cognitive outcome of children with IS remains poor in children who regress with the onset of spasms. Recovery was only observed in children who responded rapidly and completely to therapy. Yet, a subgroup of children appears to be resistant to the deleterious effects of spasms. We need to better study these children to confirm the lack of impact of spasms on their development through repeated developmental evaluations and to assess possible genetically inherited neuroprotective mechanisms.
Well-structured, prospective trials will be needed in order to throw some light on the efficacy of therapy in specific groups, their effect on patients' cognitive outcome, as well as the evolution of this disorder towards other types of epileptic syndromes.
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